4.6 Article

Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure

期刊

CIRCULATION-HEART FAILURE
卷 6, 期 5, 页码 977-987

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCHEARTFAILURE.113.000471

关键词

exercise; follow-up studies; heart failure; oxygen; prognosis

向作者/读者索取更多资源

Background In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified. We evaluated whether this finding has a prognostic meaning. Methods and Results We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment. We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient 1.05). Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death. Median follow-up was 3.01 (1.39-4.98) years. AT was identified in 1935 out of 2137 patients (90.54%). At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001). At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89). Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10). Similar results were obtained for the secondary study end point. Conclusions The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Albuminuria as a marker of systemic congestion in patients with heart failure

Eva M. Boorsma, Jozine M. Ter Maaten, Kevin Damman, Bart J. van Essen, Faiez Zannad, Dirk J. van Veldhuisen, Nilesh J. Samani, Kenneth Dickstein, Marco Metra, Gerasimos Filippatos, Chim C. Lang, Leong Ng, Stefan D. Anker, John G. Cleland, Pierpaolo Pellicori, Ron T. Gansevoort, Hiddo J. L. Heerspink, Adriaan A. Voors, Johanna E. Emmens

Summary: Albuminuria is common in patients with heart failure and is associated with clinical symptoms and biomarkers of congestion. It is also related to the severity and prognosis of heart failure.

EUROPEAN HEART JOURNAL (2023)

Review Cardiac & Cardiovascular Systems

Prevention of cardiorenal damage: importance of albuminuria

Luis M. Ruilope, Alberto Ortiz, Alejandro Lucia, Blanca Miranda, Gloria Alvarez-Llamas, Maria G. Barderas, Massimo Volpe, Gema Ruiz-Hurtado, Bertram Pitt

Summary: Chronic kidney disease (CKD) is a leading cause of death that requires early detection for effective management. The current diagnostic criteria for CKD only identify advanced stages, leaving a 'blind spot' in detection where kidney injury is present but undetectable. Elevated urinary albumin-excretion rate can predict future cardiovascular events. Implementing opportunistic or systematic albuminuria screening and therapy has the potential to improve cardiorenal outcomes and mitigate the projected burden of CKD and cardiovascular diseases in the future.

EUROPEAN HEART JOURNAL (2023)

Review Cardiac & Cardiovascular Systems

Hypertension management in patients with cardiovascular comorbidities

Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus P. Schlaich, Koon K. Teo, Raymond R. Townsend, Costas Tsioufis, Michael A. Weber, Thomas Weber, Michael Boehm

Summary: Arterial hypertension is a leading cause of death worldwide, with increasing incidence due to aging, obesity, socioeconomic and environmental changes. Lifestyle modifications and antihypertensive drugs are recommended for lowering blood pressure and reducing cardiovascular morbidity and mortality. New drugs and treatments improve cardiovascular and renal outcomes. Comorbidities often complicate management of hypertension.

EUROPEAN HEART JOURNAL (2023)

Article Environmental Sciences

The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers

Cristina Mennitti, Annaluisa Ranieri, Ersilia Nigro, Lorella Tripodi, Mariarita Brancaccio, Jacopo Ulisse, Luca Gentile, Fabio Fimiani, Arturo Cesaro, Giovanni D'Alicandro, Giuseppe Limongelli, Aurora Daniele, Raffaela Pero, Giulia Frisso, Paolo Calabro, Lucio Pastore, Maria Rosaria Licenziati, Olga Scudiero, Barbara Lombardo

Summary: This study evaluated the differences in biochemical parameters between obese children who engage in physical exercise and sedentary obese children. It found that physical exercise reduces the inflammatory state in obese children and identified a panel of biomarkers that can help prevent obesity-related complications.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2023)

Review Medicine, General & Internal

Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis

Francesca Dongiglio, Emanuele Monda, Giuseppe Palmiero, Federica Verrillo, Marta Rubino, Gaetano Diana, Annapaola Cirillo, Adelaide Fusco, Erica Vetrano, Michele Lioncino, Martina Caiazza, Giuseppe Cerciello, Laura Capodicasa, Flavia Chiosi, Vincenzo Simonelli, Maria Luisa De Rimini, Francesco Natale, Alessandro Di Santo, Elisabetta Moscarella, Paolo Calabro, Giuseppe Limongelli

Summary: Gastrointestinal involvement is common in systemic amyloidosis patients, leading to debilitating symptoms, nutrient deficiencies, and indicating disease severity. However, diagnosing gastrointestinal involvement in patients with isolated symptoms is challenging. The nutritional status in systemic amyloidosis is crucial and considered a significant prognostic factor, but defining it remains difficult due to the lack of standardized thresholds in specific populations. This review aims to provide insight into the fundamental steps of nutritional assessment using clinical and instrumental tools for improved prognostic stratification and patient management.

JOURNAL OF CLINICAL MEDICINE (2023)

Editorial Material Cardiac & Cardiovascular Systems

Editorial comments: Focus on lipid, obesity, and eating behaviour

Geza Halasz, Francesco Bandera, Massimo Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

Ovidiu Chioncel, Lina Benson, Maria G. Crespo-Leiro, Stefan D. Anker, Andrew J. S. Coats, Gerasimos Filippatos, Theresa McDonagh, Cornelia Margineanu, Alexandre Mebazaa, Marco Metra, Massimo F. Piepoli, Marianna Adamo, Giuseppe M. C. Rosano, Frank Ruschitzka, Gianluigi Savarese, Petar Seferovic, Maurizio Volterrani, Roberto Ferrari, Aldo P. Maggioni, Lars H. Lund

Summary: This study investigates the prevalence and associations of non-cardiac comorbidities (NCCs) with in-hospital and post-discharge outcomes in acute heart failure (AHF) patients with different ejection fraction (EF) categories. Multiple NCCs are associated with poor outcomes, and the association between individual comorbidities and post-discharge outcomes varies among different EF categories, suggesting the need for specific multidisciplinary management programs for different comorbidities in post-discharge phase.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Genetics & Heredity

Whole-exome sequencing: Clinical characterization of pediatric and adult Italian patients affected by different forms of hereditary cardiovascular diseases

Stefania Lenarduzzi, Beatrice Spedicati, Beatrice Alessandrini, Paola Tesolin, Alessia Paldino, Marta Gigli, Gianfranco Sinagra, Paolo Gasparini, Matteo Dal Ferro, Giorgia Girotto

Summary: This study focuses on the genetic characterization of hereditary cardiovascular diseases, including cardiomyopathies, channelopathies, and aortopathies and pulmonary arterial hypertension. The majority of patients analyzed in this study were affected by cardiomyopathies, and a higher detection rate was observed in familial forms compared to sporadic cases. Further clinical follow-up and reevaluation of genetic data will be necessary for patients with negative results.

MOLECULAR GENETICS & GENOMIC MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction

Davide Stolfo, Lars H. Lund, Gianfranco Sinagra, Felix Lindberg, Ulf Dahlstrom, Giuseppe Rosano, Gianluigi Savarese

Summary: This study found that predictors of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) and beta-blockers use in heart failure patients include hypertension, younger age, outpatient care, and specialty treatment. The use of these medications was associated with lower risk of cardiovascular mortality/hospitalization and all-cause mortality in a matched cohort. Positive control analysis confirmed these findings, and there were no associations with the negative control outcome.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Letter Cardiac & Cardiovascular Systems

Hypocapnia is an independent predictor of in-hospital mortality in acute heart failure

Alberto Guarnaccia, Gianfranco Sinagra, John G. F. Cleland

ESC HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making

Nathan Green, Yang Chen, Constantinos O'Mahony, Perry M. Elliott, Roberto Barriales-Villa, Lorenzo Monserrat, Aristides Anastasakis, Elena Biagini, Juan Ramon Gimeno, Giuseppe Limongelli, Menelaos Pavlou, Rumana Z. Omar

Summary: This study provides a contemporary cost-effectiveness analysis of using implantable cardioverter defibrillators (ICDs) for primary prevention in patients with hypertrophic cardiomyopathy (HCM). The researchers found that using a 5-year sudden cardiac death (SCD) risk threshold of 6% was cheaper and had marginally better total quality adjusted life years (QALYs) compared to current practice. The main factors driving this decision are the health-related quality of life (HRQL) attributed to ICD patients and the time horizon.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Sport Sciences

Standardised Exercise Prescription for Patients with Chronic Coronary Syndrome and/or Heart Failure: A Consensus Statement from the EXPERT Working Group

Dominique Hansen, Paul Beckers, Daniel Neunhaeuserer, Birna Bjarnason-Wehrens, Massimo F. Piepoli, Bernhard Rauch, Heinz Voeller, Ugo Corra, Esteban Garcia-Porrero, Jean-Paul Schmid, Michel Lamotte, Patrick Doherty, Rona Reibis, Josef Niebauer, Paul Dendale, Constantinos H. Davos, Evangelia Kouidi, Martijn A. Spruit, Luc Vanhees, Veronique Cornelissen, Frank Edelmann, Olga Barna, Christoph Stettler, Cajsa Tonoli, Eugenio Greco, Roberto Pedretti, Ana Abreu, Marco Ambrosetti, Simona Sarzi Braga, Maurizio Bussotti, Pompilio Faggiano, Tim Takken, Carlo Vigorito, Bernhard Schwaab, Karin Coninx

Summary: This study developed a digital training and decision support system (EXPERT tool) for exercise prescription in patients with CCS and/or CHF. The tool takes into account different risk factors, comorbidities, and cardiac devices to formulate personalized exercise prescriptions. Three patient cases are presented to demonstrate the application of the EXPERT tool.

SPORTS MEDICINE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

PARTICIPATION IN A CLINICAL TRIAL IS ASSOCIATED WITH LOWER MORTALITY IN PATIENTS WITH HEART FAILURE: OBSERVATIONS FROM THE EUROBSERVATIONAL RESEARCH PROGRAMME OF THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE LONG-TERM REGISTRY

Christos Kapelios, Lina Benson, Maria Generosa Crespo-Leiro, Stefan D. Anker, Andrew J. S. Coats, Gerasimos S. Filippatos, Mitja J. Lainscak, Theresa McDonagh, Alexandre Mebazaa, Marco Metra, Massimo Francesco Piepoli, Giuseppe Rosano, Frank Thomas Ruschitzka, Gianluigi Savarese, Petar M. Seferovic, Maurizio Volterrani, Aldo Pietro Maggioni, Lars Lund

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Review Cardiac & Cardiovascular Systems

Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials

Chiara Oriecuia, Daniela Tomasoni, Isabella Sala, Giovanni Battista Bonfioli, Marianna Adamo, Cristina Gussago, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra, Claudia Specchia

Summary: In patients with HF, regardless of their LVEF and clinical status, the addition of SGLT2i to SOC showed a significant improvement in quality of life as early as at 3-month follow-up.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Article Cell & Tissue Engineering

Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial

Satsuki Yamada, Jozef Bartunek, Thomas J. Povsic, Gad Cotter, Beth A. Davison, Christopher Edwards, Atta Behfar, Marco Metra, Gerasimos S. Filippatos, Marc Vanderheyden, William Wijns, Andre Terzic

Summary: Patients with heart failure often experience limitations in daily activities and poor quality of life. This study found that cell therapy can significantly improve the health-related quality of life in heart failure patients, particularly in those with pre-existing advanced left ventricular enlargement.

STEM CELLS TRANSLATIONAL MEDICINE (2023)

暂无数据